LRRK1 Activators
LRRK1 Activators encompass a diverse array of chemical compounds that synergistically enhance the functional activity of LRRK1 through varied intracellular signaling pathways. Forskolin and 8-Bromo-cAMP, by elevating intracellular cAMP levels, activate PKA, which is poised to phosphorylate substrates that could potentiate LRRK1's role in signaling cascades. Concurrently, the kinase inhibitor EGCG may suppress competitive kinase pathways, allowing LRRK1's pathways greater prominence within cellular signaling. The lipid mediator Sphingosine-1-phosphate and the calcium disruptor Thapsigargin enhance LRRK1 activity by modulating lipid and calcium signaling, respectively, pathways in which LRRK1 plays a critical part. Further, PMA activates PKC, thereby influencing signaling pathways that intersect with LRRK1's regulatory functions. LY294002, a PI3K inhibitor, redirects cellular signaling towards LRRK1-centric pathways by dampening PI3K/Akt pathway activity, which could indirectly result in the amplification of LRRK1 signaling.
The suite of LRRK1 activators also includes specific kinase pathway modulators that indirectly enhance LRRK1's activity. U0126 and SB203580, by inhibiting MEK1/2 and p38 MAPK respectively, shift signaling equilibria to favor pathways where LRRK1 is a critical mediator. A23187 bolsters LRRK1's activity by elevating intracellular calcium levels, thus activating calcium-dependent kinases and phosphatases that can modulate LRRK1 function. Staurosporine, despite its broad kinase inhibition profile, has the potential to selectively lift inhibitory controls on kinases that regulate LRRK1, thereby facilitating enhanced signaling through LRRK1 pathways. Together, these LRRK1 activators operate through distinct yet converging mechanisms, culminating in the upregulated activity of LRRK1, which plays a pivotal role in regulating various cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin increases intracellular cAMP levels, which in turn activates PKA. PKA can phosphorylate substrates that may interact with or alter the function of LRRK1, leading to enhanced activity of LRRK1 in its role in cellular signaling and homeostasis. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is a kinase inhibitor that can downregulate kinase pathways competitive to those of LRRK1. Through this inhibition, LRRK1-related pathways may become more prominent, leading to an increase in the functional activity of LRRK1. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $106.00 $166.00 $289.00 $550.00 $819.00 | 2 | |
As a cAMP analog, 8-Bromoadenosine 3',5'-cyclic monophosphate (8-Bromo-cAMP) increases the levels of cAMP in cells, similarly to Forskolin, and promotes PKA activation. This activation can enhance LRRK1 activity by influencing signaling pathways that LRRK1 is part of. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
This lipid signaling molecule activates sphingosine-1-phosphate receptors, which can lead to downstream effects that potentiate signaling pathways involving LRRK1, thus enhancing its activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin elevates intracellular calcium levels, which can activate calcium-dependent kinases and phosphatases that modify the activity of LRRK1, enhancing its functional role in the cell. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
As a PKC activator, PMA can modulate signaling pathways that intersect with those regulated by LRRK1, resulting in an increased functional activity of LRRK1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This compound is a p38 MAPK inhibitor and can lead to the redirection of signaling traffic towards LRRK1's pathways, indirectly enhancing the activity of LRRK1. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium levels, activating calcium-dependent signaling mechanisms that may enhance the activity of LRRK1. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Although a broad-spectrum kinase inhibitor, at specific concentrations, Staurosporine may preferentially inhibit kinases that negatively regulate LRRK1, thus enhancing LRRK1 signaling pathways. | ||||||